The answer depends on the questions you’re trying to answer, as well as the origin, quantity, and quality of your samples. In this article, we’ll briefly discuss several RNA-seq workflows, how they ...

We performed both homology-based and GUIDE-seq nomination of candidate off-target sites, which resulted in the testing of 5002 sites from four healthy donors (not shown). We then nominated additional ...

Andrew Zelenetz, MD, PhD, discusses the dual strategy of using the duration of benefit metric and re-biopsy to navigate complex sequencing decisions in targeted lymphoma therapy. A central challenge ...